MedPath

MicuRx's MRX-5 Shows Promise in Phase 1 Trial for NTM Infections

• MicuRx announced positive results from its Phase 1 clinical trial of MRX-5, an oral antibacterial agent targeting nontuberculous mycobacterial (NTM) infections. • The trial demonstrated that MRX-5 was generally well tolerated in healthy adult subjects, with no serious adverse events reported during the study. • Pharmacokinetic analysis revealed a linear and predictable profile for MRX-6038, the active metabolite of MRX-5, with food intake not significantly affecting absorption. • These Phase 1 data support further development of MRX-5 as a potential treatment for NTM infections, addressing a growing global health concern.

Shanghai MicuRx Pharmaceutical Co., Ltd. has announced the successful completion of a Phase 1 clinical trial in Australia for MRX-5, a novel oral antibacterial agent designed to combat nontuberculous mycobacterial (NTM) infections. The study, conducted at the Nucleus Network Research Center, marks a significant step forward in the development of a new treatment option for this increasingly prevalent and challenging condition.

Phase 1 Trial Details

The Phase 1 trial was a first-in-human study evaluating the safety, tolerability, pharmacokinetics (PK), and food effect of orally administered MRX-5 in healthy adult volunteers. Participants received single and multiple ascending doses of the drug.
Key findings from the trial include:
  • MRX-5 was generally well tolerated, with no serious adverse events (SAEs) reported.
  • The majority of treatment-emergent adverse events (TEAEs) were mild (CTCAE Grade 1) and resolved without intervention.
  • Pharmacokinetic analysis showed that MRX-6038, the active metabolite of MRX-5, exhibited a linear and predictable PK profile after single oral doses ranging from 50mg to 1200mg.
  • Food intake did not significantly affect the absorption of MRX-5.

Potential Impact on NTM Treatment

NTM infections are on the rise globally, and current treatment options are limited. These infections, caused by mycobacteria other than Mycobacterium tuberculosis and Mycobacterium leprae, can lead to lesions in various tissues and organs, with NTM lung disease being the most common manifestation. Current treatments typically involve multidrug combination therapy with antibiotics, which can be lengthy, associated with drug resistance, and have significant adverse effects.
MRX-5, a novel benzoxazole antibiotic, has demonstrated potent antibacterial activity against NTM pathogens in preclinical studies. It is specifically developed for the treatment of NTM pulmonary disease and offers potential advantages such as high specificity, oral bioavailability, low resistance rates, and a favorable safety profile. The company plans to explore an all-oral treatment strategy incorporating MRX-5 to provide safer and more effective options for treating NTM infections.

About MRX-5

MRX-5 is designed to address the increasing incidence and prevalence of NTM diseases. It has shown minimal interactions, low resistance potential, and high oral bioavailability, making it suitable for long-term use in treating chronic infections. The successful completion of the Phase 1 trial supports the further development of MRX-5 as a potential new treatment for NTM infections.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cyclarity Therapeutics Launches First-in-Human Trial of UDP-003 for Atherosclerosis

Cyclarity Therapeutics has initiated a Phase 1 clinical trial in Australia to evaluate UDP-003, a drug targeting atherosclerosis.
The trial will assess the safety and potential efficacy of UDP-003 in removing arterial plaques by targeting oxidized cholesterol.

FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM Infections

The FDA has granted Orphan Drug Designation to MicuRx's MRX-5 for treating non-tuberculous mycobacteria (NTM) infections, a significant step for MicuRx.
MRX-5, a novel benzoxazole antibiotic, targets drug-resistant NTM infections and has demonstrated promising antibacterial activity and safety profiles in studies.

Russia Begins Clinical Trials of Novel Meningococcal Vaccine Targeting Five Serotypes

Russia's FMBA has initiated Phase I clinical trials for MCV-5, a novel vaccine against five serotypes (A, B, C, W, and Y) of meningococcus, a leading cause of meningitis.
Preclinical trials have demonstrated the vaccine's safety, immunogenicity, and protective capabilities, paving the way for human trials to assess its efficacy.

Traws Pharma's Tivoxavir Marboxil Shows Promise as Single-Dose H5N1 Bird Flu Treatment

Traws Pharma's Tivoxavir Marboxil demonstrates encouraging results as a single-dose treatment for H5N1 avian influenza, marking a potential breakthrough.
Phase 1 trial data reveals that a single dose of Tivoxavir Marboxil maintains plasma drug levels above the effective concentration for over 23 days.

Alumis' A-005 Shows Promise in Phase 1 Trial for CNS Penetration and TYK2 Inhibition

Alumis' A-005, a selective TYK2 inhibitor, demonstrates successful blood-brain barrier penetration in a Phase 1 trial with healthy subjects.
The trial confirms A-005's safety, tolerability, and favorable pharmacokinetics, showing significant drug exposure in the cerebral spinal fluid.

Merus' Petosemtamab Enters Phase 2 Trial for Heavily Pretreated Metastatic Colorectal Cancer

Merus N.V. has initiated a Phase 2 clinical trial of petosemtamab as a monotherapy for patients with heavily pretreated (3L+) metastatic colorectal cancer (mCRC).
The open-label trial will assess the safety and anti-tumor activity of petosemtamab in mCRC patients who have progressed after anti-EGFR therapy.

MicuRx's MRX-4 Meets Primary Endpoint in Phase III cSSTI Trial

MicuRx's MRX-4 for injection, transitioning to oral Contezolid, demonstrated non-inferiority to intravenous Linezolid in treating complex skin and soft tissue infections (cSSTI).
The Phase III trial in China showed MRX-4/Contezolid had good clinical and microbiological efficacy, meeting the primary endpoint for cSSTI treatment.

Pimicotinib Shows Positive Phase 3 Results in Tenosynovial Giant Cell Tumors

Pimicotinib demonstrated a 54% objective response rate at week 25, significantly higher than the 3.2% observed in the placebo group in TGCT patients.
The MANEUVER trial confirmed pimicotinib's potential as a new treatment option by showing statistically significant improvements in patient outcomes, including reduced stiffness and pain.

Foresee's Linvemastat Shows Promising Safety Profile in Phase 1 Trial

Foresee Pharmaceuticals' linvemastat (FP-020), a novel oral MMP-12 inhibitor, demonstrates a favorable safety and tolerability profile in a Phase 1 clinical trial.
The Phase 1 study evaluated single and multiple ascending doses of linvemastat in healthy volunteers, with no serious adverse events reported.

Monopar Therapeutics Initiates Phase 1a Trial of uPAR-Targeted Radiopharmaceutical MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics has commenced a Phase 1a clinical trial for MNPR-101-Lu, a novel radiopharmaceutical targeting urokinase plasminogen activator receptor (uPAR) in advanced solid tumors.
The open-label, dose-escalation study will initially enroll patients already participating in the MNPR-101-Zr imaging trial to identify those most likely to benefit from the therapy.

Reference News

[1]
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
prnewswire.com · Oct 25, 2024

Shanghai MicuRx Pharmaceutical Co., Ltd. announced the successful completion of Phase I clinical trial of MRX-5 in Austr...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy